Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight increase in price, with significant net inflows from major funds, indicating potential investor interest despite some outflows from retail investors [1][2]. Financial Performance - As of November 20, 2025, Meihao Medical's stock closed at 21.12 yuan, up 0.62%, with a trading volume of 30,300 lots and a total transaction value of 63.8864 million yuan [1]. - In the third quarter of 2025, the company reported a main business revenue of 462 million yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 93.9002 million yuan, a year-on-year increase of 5.89% [3]. - For the first three quarters of 2025, the company's main revenue was 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit decreased by 19.25% to 208 million yuan [3]. Market Position and Valuation - Meihao Medical's total market capitalization is 12.015 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan [3]. - The company's price-to-earnings ratio (P/E) is 43.28, which is lower than the industry average of 55.37, indicating a relatively favorable valuation [3]. - The gross profit margin stands at 39.34%, significantly lower than the industry average of 51.22%, while the net profit margin is 17.43%, higher than the industry average of 9.57% [3]. Institutional Ratings - Over the past 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, suggesting a positive outlook from analysts [4]. - The average target price set by institutions for the stock is 25.2 yuan, indicating potential upside from the current trading price [4].
股票行情快报：美好医疗（301363）11月20日主力资金净买入1096.21万元